The General Director of the Spanish National Center for Cardiovascular Research (CNIC), Dr. Valentín Fuster, has been chosen by the World Heart Federation (WHF) to deliver its first Inaugural Lecture, as part of the European Society of Cardiology Congress (ESC Congress 2025) and alongside the WHF World Congress of Cardiology, both of which are being held in Madrid. This award, which the WHF is instituting for the first time, recognizes individuals who have made outstanding contributions to global cardiovascular health and who represent excellence in clinical practice, research, education, and leadership. 

“About 80% of fatal and non-fatal cardiovascular diseases occur in low- and middle-income countries, so we must think globally about health and education. I am very grateful for this honor bestowed upon me by the WHF,” said Dr. Fuster, who is also president of Mount Sinai Fuster Heart Hospital in New York and Physician-in-Chief of Mount Sinai Hospital.

In his speech, Dr. Fuster addresses the need to promote cardiovascular health from childhood as an essential strategy for reducing the risk of heart disease worldwide. His presentation, entitled “Primordial prevention: An unexplored window of opportunity,” highlights decades of pioneering work in large-scale educational programs developed in Spain, New York, and Colombia, focusing on school-age children.

Dr. Fuster: Early education is the most powerful tool
for achieving a lasting impact on global health

These projects, which involve students, teachers, families, and communities, are based on promoting healthy lifestyle habits (balanced diet, physical activity, knowledge of the body and heart, and emotional management). Studies led by Dr. Fuster, published in leading scientific journals such as the Journal of the American College of Cardiology, have demonstrated significant positive changes in the knowledge, attitudes, and habits of thousands of children who participated in these programs.

“Cardiovascular prevention must begin in the early stages of life. Early education is the most powerful tool for achieving a lasting impact on global health,” says Dr. Fuster.

The president of the World Heart Federation, Jagat Narula, emphasizes that “Dr. Fuster is a prominent leader in cardiovascular medicine. His contributions in this field and in the prevention and treatment of heart disease worldwide are enormous and will set a high standard of intellectual leadership and innovation for years to come, as well as a very high bar for future award winners.”

With a track record of leadership in both Spain and the United States, Dr. Fuster has consolidated the CNIC and Mount Sinai Fuster Heart Hospital as international centers of excellence in cardiovascular disease research, prevention, and treatment.

An international clinical trial coordinated by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with the Mario Negri Institute for Pharmacological Research in Milan, has found that beta-blockers—drugs commonly prescribed for a range of cardiac conditions—offer no clinical benefit for patients who have had an uncomplicated myocardial infarction (i.e., without deterioration of the heart function after the event).

The findings—published in two articles in The New England Journal of Medicine and The Lancet and presented today during a “Hot Line” session at the European Society of Cardiology (ESC) Congress in Madrid—overturn a treatment paradigm that has shaped clinical practice for more than four decades.

The REBOOT trial (Treatment with Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction) enrolled 8,505 patients with a left ventricular ejection fraction above 40% after a heart attack, across 109 hospitals in Spain and Italy. Participants were randomly assigned to receive or not receive beta-blockers after hospital discharge. All patients received current standard of care and were followed for a median of nearly four years. The results showed no significant differences between the two groups in rates of death, recurrent heart attack, or hospitalization for heart failure.

Although generally considered safe, beta-blockers can cause side effects such as fatigue, bradycardia (low heart rate), and sexual dysfunction.

“REBOOT will change clinical practice worldwide,” says principal investigator Dr. Borja Ibáñez, CNIC Scientific Director, cardiologist at Hospital Universitario Fundación Jiménez Díaz, and a group leader in the Spanish cardiovascular research network CIBERCV. “Currently, more than 80% of patients with uncomplicated myocardial infarction are discharged on beta-blockers. The REBOOT findings represent one of the most significant advances in heart attack treatment in decades.”

After a heart attack, cardiac contractile function can be overtly deteriorated (left ventricular ejection fraction below 40%), moderately reduced (40-50%), or preserved (above 50%). The vast majority patients these days (approx. 70%) survive the heart attach with a preserved cardiac function, a smaller proportion (approx. 20%) with a moderately reduced function, and 10% with overtly reduced cardiac function. REBOOT enrolled patients from the 2 former groups since there was no evidence of the benefits of beta-blockers on these types of patients. While the trial results showed no benefit of beta-blockers for the study population overall, the treatment did appear to benefit the patient subgroup with moderately reduced contractile function. However, this subgroup constituted a relatively small proportion of the study population, and the small sample size prevented the team from drawing firm conclusions on this subgroup.

To address this question in this specific subgroup of patients, the researchers carried out a joint meta-analysis with other smaller trials that also included patients with these characteristics. The meta-analysis, published in The Lancet, confirms that beta-blockers significantly reduce the risk of death, recurrent heart attack, or heart failure only in post-infarction patients with moderately reduced cardiac contractile function.

Dr. Xavier Rosselló—CNIC scientist, cardiologist at University Hospital Son Espases in Mallorca, and one of the REBOOT study leaders—explains: “Taken together, these two studies provide compelling evidence that post-infarction patients with fully preserved contractile function (ejection fraction above 50%) do not benefit from beta-blockers, whereas those with moderate or greater dysfunction (ejection fraction below 50%) do.”

Dr. Borja Ibáñez, who led the meta-analysis, adds: “These findings will form the basis for future treatment of myocardial infarction and will drive a major shift in clinical practice guidelines.”

Every year, more than 2 million people in Europe suffer a heart attack, including around 70,000 in Spain. Until now, the majority were discharged on beta-blockers—a practice now called into question.

“After a heart attack, patients are typically prescribed multiple medications, which can make adherence difficult,” explains Dr. Ibáñez. “Beta-blockers were added to standard treatment early on because they significantly reduced mortality at the time. Their benefits were linked to reduced cardiac oxygen demand and arrhythmia prevention. But therapies have evolved. Today, occluded coronary arteries are systematically reopened rapidly, drastically lowering the risk of serious complications such as arrhythmias. In this new context—where the extent of heart damage is smaller—the need for beta-blockers is unclear. While we often test new drugs, it’s much less common to rigorously question the continued need for older treatments.”
That was the motivation behind REBOOT-CNIC. “The trial was designed to optimize heart attack care based on solid scientific evidence and without commercial bias,” said Dr. Ibáñez. “These results will help simplify and streamline treatment, reduce adverse effects, and improve the quality of life for thousands of patients every year.”
Importantly, REBOOT was conducted without pharmaceutical industry funding.

A landmark in European cardiovascular research

More than 500 researchers from across Spain and Italy participated in REBOOT on a voluntary basis. A total of 109 hospitals—74 in Spain and 35 in Italy—recruited 8,505 patients. The Italian arm was coordinated by the Mario Negri Institute in Milan under the leadership of cardiologist Roberto Latini, through a collaboration agreement with the CNIC.

As Dr. Rosselló explains: “The credit for carrying out the largest clinical trial ever conducted on this question belongs not only to CNIC, but above all to the more than 100 participating hospitals and their teams, who worked tirelessly for six years with the sole aim of improving care for heart attack patients worldwide.”

Through its Clinical Trials Coordination Unit (CTCU), the CNIC led the logistics and management of the trial, showcasing the Spanish research system’s capacity to deliver clinical studies with global impact. The CTCU has become a key hub for coordinating large-scale cardiology trials with a purely scientific mission.

The success of REBOOT also relied on the collaboration between the CNIC, the Spanish Society of Cardiology (SEC), and CIBERCV. According to SEC president Dr. Luis Rodríguez Padial, “REBOOT not only changes heart attack treatment—it also changes how clinical trials are designed and run in Spain.”

Underlining this point, Dr. Ibáñez emphasizes that the joint leadership by CNIC, SEC, and CIBERCV “reflects Spain’s enormous potential when a transformative project is combined with strong scientific leadership.”

Dr. Valentín Fuster, CNIC General Director, President of Mount Sinai Fuster Heart Hospital , and one of the senior investigators on REBOOT, notes: “This trial will reshape all international clinical guidelines. It joins other landmark trials led by CNIC—such as SECURE with the polypill and DapaTAVI, which links SGLT2 inhibition to TAVI—that have already transformed the global approach to cardiovascular disease.”

The trial was funded by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) an affiliate center of the Carlos III Health Institute (ISCIII), an executive agency of the Spanish Ministry of Science, Innovation and Universities. The clinical trial was carried out with the collaboration of the Spanish Society of Cardiology (SEC), and CIBERCV.

• Rosselló, X., Prescott, E., Kristensen, A. M., Ibanez, B., et al. (2025). Beta-blockers after myocardial infarction in patients without heart failure. The New England Journal of Medicine. Advance online publication. https://doi.org/10.1056/NEJMoa2505985
• Rosselló, X., Prescott, E., Kristensen, A. M., Ibanez, B., et al. (2025). Beta-blockers after myocardial infarction with mildly reduced ejection fraction: An individual patient data meta-analysis of randomised controlled trials. The Lancet. Advance online publication. https://doi.org/10.1016/S0140-6736(25)01592-2

Hospitals and centers participating in the REBOOT trial 

1. Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, España
2. Departamento de Cardiología, Hospital Universitario Fundación Jiménez Díaz e Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, España
3. Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), España
4. Department of Acute Brain and Cardiovascular Injury, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milán, Italia
5. Departamento de Cardiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Islas Baleares y Universitat de les Illes Balears (UIB), Palma de Mallorca, España
6. Departamento de Medicina Interna, Universidad de La Laguna, y Departamento de Cardiología, Hospital Universitario de Canarias; Instituto de Investigación Sanitaria de Canarias, Tenerife, España
7. Hospital Universitario de León, España
8. Departamento de Cardiología, Ospedale Guglielmo da Saliceto, Piacenza, Italia
9. Departamento de Cardiología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), España
10. Departamento de Cardiología, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, España
11. Departamento de Cardiología, Hospital Universitari Vall d’Hebron, Barcelona, España
12. Departamento de Cardiología, Hospital Universitario Álvaro Cunqueiro, Vigo, España
13. Department of Medical Statistics, London School of Hygiene and Tropical Medicine, Londres, Reino Unido
14. Grupo Jóvenes Cardiólogos, Sociedad Española de Cardiología (SEC), Madrid, España
15. Hospital de Burgos, España
16. Servicio de Cardiología, Complexo Hospitalario Universitario de A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, España
17. Departamento de Cardiología, Hospital Ruber Juan Bravo Quirónsalud y Facultad de Medicina, Salud y Deporte, Universidad Europea, Madrid, España
18. Cardiology Division, San Luigi Gonzaga University Hospital, Orbassano, Turín, Italia
19. Hospital Marqués de Valdecilla, IDIVAL, Santander, España
20. Departamento de Cardiología, Ospedale S. Anna e S. Sebastiano, Caserta, Italia
21. Hospital Universitario Virgen del Rocío, Sevilla, España
22. Hospital Universitario San Cecilio, Granada, España
23. Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Universidad Complutense de Madrid, España
24. Hospital de Jaén, España
25. Dipartimento di Cardiologia, Ospedale Bolognini, Seriate, Italia
26. Hospital San Juan de la Cruz, Úbeda, España
27. Hospital Virgen de los Lirios, Alcoy, España
28. Departamento de Cardiología, Complejo Hospitalario Universitario de Santiago de Compostela, IDIS, España
29. Hospital San Agustín de Avilés, España
30. Hospital Lucus Augusti, Lugo, España
31. Departamento de Cardiología, Hospital Clínic Barcelona; Institut d’Investigació August Pi i Sunyer (IDIBAPS); Universitat de Barcelona, España
32. Departamento de Cardiología, Hospital Universitario de Torrejón, Universidad Francisco de Vitoria, Madrid, España
33. Hospital Joan XXIII, Tarragona, España
34. Hospital Universitario Virgen de la Macarena, Sevilla, España
35. Departamento de Cardiología, Hospital Virgen de la Arrixaca, IMIB-Arrixaca y Universidad de Murcia, España
36. Hospital Arnau de Vilanova, Lleida, España
37. Hospital Clínico Universitario de Valladolid, España
38. Departamento Cardiovascular, Misericordia Hospital, Grosseto, Italia
39. Departamento de Cardiología, Hospital Universitari i Politècnic La Fe, Valencia, España
40. University Hospital La Luz, Madrid, España
41. Ospedale San Filippo Neri, Italia
42. Hospital Universitario Miguel Servet, Zaragoza, España
43. Hospital de Navarra, España
44. Hospital San Juan, Alicante, España
45. Hospital Clínico San Carlos, IdISSC, Universidad Complutense, Madrid, España
46. Ospedale San Paolo, Bari, Italia
47. Hospital Montecelo, Pontevedra, España
48. Ospedale Civile di Legnano, Italia
49. Hospital Maggiore di Bologna, Italia
50. Ospedale di Udine, Italia
51. Ospedale Gualdo Tadino, Gubbio, Italia
52. U.O.C. Cardiologia Ospedaliera, PO ASMN, Azienda USL di Reggio Emilia – IRCCS, Italia
53. Departamento de Cardiología, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, y Facultad de Medicina, Universidad Complutense de Madrid, España
54. Ospedale di Vaio, Fidenza, Italia
55. Departamento de Cardiología e ICCU, AOU delle Marche, Ancona, Italia
56. Hospital Universitario Fundación Alcorcón, Madrid, España
57. Unidad Cardiovascular, Ospedale Infermi, Rimini, Italia
58. Mount Sinai Fuster Heart Hospital, Nueva York, NY, EE. UU.

A major new analysis from REBOOT (Treatment with Beta-blockers after Myocardial Infarction without Reduced Ejection Fraction) clinical trial, an international study coordinated by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published at the European Heart Journal has revealed important sex-specific differences in the effects of beta-blockers following heart attacks, raising questions about long-standing treatment practices.

REBOOT, presented in a Hotline session of the ESC Congress in Madrid, is the largest contemporaneous trial testing the effect of beta-blockers in patients who survive myocardial infarction without a moderate or severe deterioration of their cardiac function (i.e. left ventricular ejection fraction greater than 40%). 8,505 patients were included across 109 hospitals in Spain and Italy. While the proportion of women in the trial was not high (something common in most myocardial infarction trials), the total number of women is the largest ever included in a trial testing beta-blockers after infarction, providing high power to the analysis performed. Patients were randomly assigned to receive Beta-blockers—a commonly prescribed drug—or no beta-blocker, while continuing to receive standard post-heart attack care. Patients were followed for a median of nearly four years.

The analysis uncovers notable sex-specific differences: while men experienced no benefit or risk when treated with beta-blockers, women treated with Beta-blockers had a significant increased risk of death, reinfarction, or hospitalization for heart failure compared to women not receiving the drug. Women treated with beta-blockers had a 2.7% higher absolute risk of mortality than those not treated with beta-blockers during the 3.7 years of follow-up of the study.

Women presenting with infarction had a worse cardiovascular profile

The elevated risk when treated with beta-blockers was restricted to women with a complete normal cardiac function after infarction (i.e. left ventricular ejection fraction of 50% or higher). Those with a mild deterioration in cardiac function did not have an excess risk of adverse outcomes when treated with beta-blockers.

Another important finding from this pre-specified analysis of the REBOOT trial is that women presenting with infarction had a worse cardiovascular profile. They were older, had more comorbidities (including higher prevalence of hypertension diabetes and dyslipidemia), and more frequently experienced heart attacks without obstructive coronary arteries (6% vs 2% in men). In addition, while overall prescription rates of secondary prevention interventions were high for all patients in the trial, women were less often prescribed some guideline-recommended therapies such as antiplatelets, statins, angiotensin-converting enzyme inhibitors (ACE), angiotensin receptor blockers (ARBs) or cardiac rehabilitation.

Of note, overall, women had a significantly worse prognosis than men (mortality across study duration was 4.3% in women vs. 3.6% in men). The Principal Investigator of the REBOOT trial, Dr. Borja Ibáñez, CNIC Scientific Director, cardiologist at Hospital Universitario Fundación Jiménez Díaz, and member of the CIBERCV, says “these findings confirm previous observational data but in a rigorous prospective trial: women presenting with infarction have worse cardiovascular profile and, more importantly, have worse prognosis than men. Our data also shows that they respond differently to a commonly prescribed intervention, beta-blockers in this case”.

Xavier Rosselló, scientist at CNIC, cardiologist at University Hospital Son Espases in Mallorca and another leader of the REBOOT trial emphasizes that “Our findings suggest that a one-size-fits-all approach may not be appropriate and that sex-specific considerations are crucial for cardiovascular interventions prescriptions.”

The trial’s results underscore the importance of
personalizing post-heart attack therapy

The REBOOT trial was coordinated by the CNIC, in collaboration with the Mario Negri Institute for Pharmacological Research in Milano, Italy. As the largest independent study of its kind, it provides critical insights into how modern post-heart attack treatments should consider patient sex, heart function, and dosing strategies. “In many cases, prescribing Beta-blockers to women after uncomplicated heart attack may do more harm than good,” Dr. Ibáñez added. “Clinicians should carefully weigh the risks and benefits, and consider dose adjustments or alternative therapies when treating female patients.”

The trial’s results underscore the importance of personalizing post-heart attack therapy. By highlighting how sex-specific factors influence the safety and effectiveness of commonly used drugs, REBOOT could reshape guidelines and improve outcomes for women worldwide.

Dr. Valentín Fuster, CNIC General Director, President of Mount Sinai Fuster Heart Hospital, and another investigator of REBOOT trial, notes: “We have been investigating sex-differences in cardiovascular disease for a long time. We already knew that cardiovascular disease presentation is different in women and men, and this study significantly adds to this knowledge by showing that response to medications is not necessarily equal in women and men. This study should spark the much-needed sex-specific approach for cardiovascular disease”.

The REBOOT trial was funded by the CNIC, an affiliate center of the Carlos III Health Institute (ISCIII), an executive agency of the Spanish Ministry of Science, Innovation and Universities. The clinical trial was carried out with the collaboration of the Spanish Society of Cardiology (SEC), and CIBERCV.

• Rossello X, Domiguez-Rodriguez A, Latini R … and Ibanez B, et al. Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. Eur Heart J. 2025; DOI: 10.1093/eurheartj/ehaf673

Un nuevo estudio del Consorcio de Psiquiatría Genómica, en el que participa el Dr. Claudio Toma, investigador del CSIC en el Centro de Biología Molecular Severo Ochoa (CBM-CSIC-UAM), ha logrado avanzar en la comprensión de los mecanismos genéticos del trastorno bipolar. Gracias a nuevas técnicas de análisis genético, han identificado genes que podrían estar directamente relacionados con esta enfermedad mental.

Del mapa genético a los genes concretos

Hasta ahora, los estudios genéticos ya habían detectado más de 60 zonas del ADN humano que parecen estar relacionadas con el trastorno bipolar. Sin embargo, esas zonas eran muy amplias y no se sabía con exactitud qué cambios genéticos concretos (llamados variantes) eran los responsables, ni qué genes estaban realmente involucrados.

Para afinar esa búsqueda, el equipo usó técnicas de mapeo fino del genoma mediante complejos análisis computacionales, que permiten localizar con más precisión las variantes que contribuyen al riego de padecer la enfermedad. Utilizando una combinación de 16 métodos distintos —incluyendo modelos estadísticos y datos biológicos sobre cómo funciona el cerebro— consiguieron reducir la lista a 17 variantes genéticas con muchas probabilidades de estar implicadas funcionalmente a genes.

“Estas variantes están relacionadas con genes clave para el funcionamiento de las neuronas y el desarrollo del cerebro. Es decir, afectan procesos fundamentales del sistema nervioso, lo que podría explicar parte del origen del trastorno”, indica Toma. “Algunos de estos genes ya se conocían por su papel en el cerebro, mientras que otros son nuevos candidatos a investigar.”

Hacia una medicina personalizada en salud mental

Además, los investigadores demostraron que estas variantes genéticas pueden mejorar las llamadas puntuaciones de riesgo genético, una herramienta que sirve para estimar si una persona tiene un mayor riesgo hereditario de desarrollar una enfermedad. Esto es especialmente útil en enfermedades complejas como el trastorno bipolar, que dependen de la interacción de muchos genes distintos.

Por último, el equipo ha desarrollado una nueva plataforma informática de alto rendimiento, que permitirá a otros investigadores seguir avanzando en este campo más rápidamente y con mayor precisión.

Este trabajo supone un avance hacia una medicina personalizada en salud mental, es decir, tratamientos y estrategias de prevención adaptados al perfil genético de cada persona. Para quienes viven con trastorno bipolar, estos descubrimientos abren nuevas vías de esperanza hacia mejores tratamientos en el futuro.

Referencia

Koromina M, Ravi A, Panagiotaropoulou G, et al. Fine-mapping genomic loci refines bipolar disorder risk genes. Nat Neurosci. 2025 Jul;28(7):1393-1403. doi: 10.1038/s41593-025-01998-z

La entrada Avance clave en la genética del trastorno bipolar: descubren genes clave implicados en la enfermedad se publicó primero en Centro de Biología Molecular Severo Ochoa.